InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board

InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board

One of The Seed Investor’s previous picks has added more expertise to its Scientific Advisory Board. 

Read Release Below: 

InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today the addition of Dr. Steven M. Dinh to its Scientific Advisory Board.

Dr. Dinh brings more than 30 years of pharmaceutical and biotech executive leadership to InMed, with proven success in developing and commercializing dermal pharmaceutical products by applying innovative drug delivery technologies. His accomplishments in pharmaceutical product development and drug delivery technology innovations have resulted in over 22 issued U.S. patents, 44 published patent applications, 6 NDA approvals and the successful commercialization of 9 products to serve the unmet needs of patients. Dr. Dinh currently serves on the Editorial Board of Therapeutic Delivery. In addition, Dr. Dinh is a Fellow of the American Association of Pharmaceutical Scientists, and a Fellow of the American Institute for Medical and Biological Engineering. He received his doctoral degree from the Massachusetts Institute of Technology.

Eric A. Adams, President and Chief Executive Officer of InMed, commented “As we approach human trials with INM-750 for the treatment of Epidermolysis Bullosa (“EB”), Dr. Dinh’s experience in the development of dermatology-focused therapeutics, with a true expertise in drug delivery, will be a highly value-added skill set for InMed.”  Mr. Adams added, “he will be instrumental in helping our scientific staff transition the program from pre-clinical development to being on the doorstep of our first human trials.”  Mr. Adam’s concluded, “We are pleased to add Dr. Dinh to our Scientific Advisory Board.”

“I’m sincerely impressed with InMed’s science-rich R&D pipeline and platform,” commented Dr. Dinh. “Clearly, EB is a devastating disease, and I believe InMed’s cannabinoid-focused scientific approach is novel, differentiated and promising. I’m looking forward to working closely with InMed’s world class teams in advancing INM-750 through clinical development to regulatory approval.”

About InMed:
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit


Published at Wed, 06 Mar 2019 16:32:41 +0000